Wednesday, September 30, 2020

USFDA

 Source: https://www.expresspharma.in/drug-approvals/pfizer-get-usfda-nod-for-xeljanz-tofacitinib-to-treat-active-polyarticular-course-juvenile-idiopathic-arthritis/

Pfizer get USFDA nod for XELJANZ (tofacitinib) to treat active polyarticular course juvenile idiopathic arthritis

Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight